Furthermore, a related study that explored the correlation between sarcopenia in castration-resistant prostate cancer (CRPC) and treatment outcomes with androgen receptor axial therapy (ARATs) revealed that the latter could potentially offer enhanced efficacy among CRPC patients with sarcopenia, compared to those devoid of it (95). This evidence concerns the gene AR and sarcopenia.